[Targeting angiogenesis in oncology].
Advances in biology have lead to the characterization of the molecular mechanisms underlying angiogenesis, a crucial process of tumor growth. Tumor cells secrete various growth factors, including VEGF, which activate endothelial cells to form new blood vessels. Numerous drugs, at present in clinical development, interfere with the molecular mediators of angiogenesis. The death of neovessels achieved by some of such compounds allows reduction in tumor size. This review describes many angiogenesic inhibitors which mechanisms of action are quite diverse.
Fayette
J
J
Département de médecine, institut Gustave-Roussy, Villejuif, France. jfayette@9online.fr
Soria
J-C
JC
Armand
J-P
JP
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D018919:Neovascularization, Physiologic; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A